Both Cyanotech Corporation (NASDAQ:CYAN) and InflaRx N.V. (NASDAQ:IFRX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Demonstrates Cyanotech Corporation and InflaRx N.V. earnings per share (EPS), gross revenue and valuation.
Table 2 provides Cyanotech Corporation and InflaRx N.V.’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
Cyanotech Corporation’s Current Ratio and Quick Ratio are 1.8 and 0.4 respectively. The Current Ratio and Quick Ratio of its competitor InflaRx N.V. are 18.7 and 18.7 respectively. InflaRx N.V. therefore has a better chance of paying off short and long-term obligations compared to Cyanotech Corporation.
Institutional & Insider Ownership
Institutional investors held 28.1% of Cyanotech Corporation shares and 58.4% of InflaRx N.V. shares. Insiders held roughly 15% of Cyanotech Corporation’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
For the past year Cyanotech Corporation has stronger performance than InflaRx N.V.
Cyanotech Corporation beats on 6 of the 9 factors InflaRx N.V.
Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition market worldwide. The companyÂ’s products include Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids; and Hawaiian BioAstin natural astaxanthin, a dietary antioxidant, which is used as a human nutraceutical and functional food ingredient to support and maintain the bodyÂ’s natural inflammatory response, enhance skin, and support eye and joint health. Cyanotech Corporation sells its products in bulk quantities to manufacturers, formulators, and distributors in the health foods and nutritional supplements markets; and as packaged consumer products to distributors, retailers, and direct consumers. The company also sells its products online at nutrex-hawaii.com. Cyanotech Corporation was founded in 1983 and is headquartered in Kailua-Kona, Hawaii.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.